Novaliq’s Vevizye® Gets Positive CHMP Opinion for Dry Eye Disease
Novaliq, a biopharmaceutical company specializing in innovative ocular therapies using EyeSol® waterless technology, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Vevizye®. This product is aimed at…
Cardio Diagnostics Unveils CDIO.AI: New Website Showcases AI-Driven Cardiovascular Solutions
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a frontrunner in AI-driven cardiovascular medicine, has unveiled its newly redesigned website, CDIO.AI. This upgraded platform underscores the Company’s commitment to an AI-first approach and showcases its advanced, scalable solutions for preventing, detecting, and…
Hologic Reports Q3 Fiscal 2024 Financial Results
Hologic, Inc. (Nasdaq: HOLX) has announced its financial results for the fiscal third quarter ending June 29, 2024. “We delivered another strong financial performance in Q3 2024, marked by sequential improvements in our operating margin and robust cash flow,” said…
NovaBay Pharmaceuticals Closes $3.87M Public Offering with Partial Overallotment Exercise
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has announced the successful closing of its underwritten public offering, which included common stock, pre-funded warrants, and Series F-1, F-2, and F-3 warrants, raising approximately $3.87 million before underwriting discounts and expenses. This total…
Battelle to Help Medical Device Companies Navigate New ‘Forever Chemicals’ Regulations
Battelle, renowned for its extensive expertise in research, laboratory analysis, and consulting on Per- and Polyfluoroalkyl Substances (PFAS), is now leveraging its skills in response to the growing awareness and regulation of these chemicals. With increasing federal regulations like the…
Tandem and Dexcom’s t:slim X2 Insulin Pump with Dexcom G7 CGM Approved for Sale in Canada
Tandem Diabetes Care and Dexcom Announce Compatibility of t:slim X2 Insulin Pump with Dexcom G7 CGM in Canada Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM) have announced that the updated software for the t:slim X2™ insulin…
Amneal Gets FDA Approval for Potassium Phosphates IV Bags
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that it has received New Drug Application (NDA) approval from the U.S. Food and Drug Administration (FDA) for its new potassium phosphates in 0.9% sodium chloride IV bags. This new ready-to-use (RTU) sterile…
Good Neighbor Pharmacy Honors Independent Pharmacies at ThoughtSpot 2024
Good Neighbor Pharmacy, a national network under Cencora, celebrated independent pharmacy excellence at its annual conference, ThoughtSpot 2024, held from July 24-27 at the Marriott World Center in Orlando, Fla. Now in its 13th year, ThoughtSpot gathered over 3,500 pharmacy…
Centene Reports Q2 2024 Results
Centene Corporation (NYSE: CNC) has announced its financial results for the second quarter ending June 30, 2024. Here’s a summary of the key figures: Note: Adjusted EPS and SG&A Expense Ratios are non-GAAP financial measures. Reconciliations are available in the…
HCA Healthcare Q2 2024 Earnings Report
HCA Healthcare, Inc. (NYSE: HCA) reported its financial and operational results for Q2 2024, ending June 30, 2024. Here are the key highlights: Second Quarter Highlights: Six-Month Summary: Balance Sheet & Cash Flow: Dividend Declaration: Revised 2024 Guidance: Outlook:The revised…
CVS Caremark® Sets New Standards for Pharmacy Benefit Management
CVS Caremark®, the top pharmacy benefit manager and a division of CVS Health® (NYSE: CVS), has announced a new commitment to enhance pharmacy benefits for American businesses, unions, and health plans. This initiative aims to offer greater transparency, lower drug…
Bristol Myers Squibb Q2 2024 Financial Results
Bristol Myers Squibb (NYSE: BMY) has announced its financial results for Q2 2024. Highlights: Second Quarter Financials: Product Revenue Highlights: Product and Pipeline Updates: Financial Guidance for 2024: Bristol Myers Squibb’s Q2 2024 results reflect ongoing efforts to drive growth…